First diagnostic results from Gothenburg-2 screening trial




Download data is not yet available.


Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa N, Nelen V, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43–51. DOI:

Xie J, Jun C, Liu M, Sun K, Jin Z, Ding Z, Gong X. MRI/transrectal ultrasound fusion-guided targeted biopsy and transrectal ultrasound-guided systematic biopsy for diagnosis of prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:880336. DOI:

Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126–37. DOI:

Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385:908–20. DOI:

Auvinen A, Rannikko A, Taari K, Kujala P, Mirtti T, Kenttämies A, et al. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale. Eur J Epidemiol. 2017;32:521–7. DOI:



How to Cite

Bratt, O., & Auvinen, A. (2023). First diagnostic results from Gothenburg-2 screening trial. Scandinavian Journal of Urology, 58, 2–3.



News and views

Most read articles by the same author(s)

1 2 > >>